Skip to main content
SpringerLink
Log in

Systemische Therapie maligner Nebennierentumoren

Systemic therapy of malignant adrenal tumors

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Die systemische Therapie progredienter maligner Nebennierentumoren erfolgt in der Regel im Rahmen eines palliativ orientierten Therapiekonzepts. Etablierter therapeutischer Ansatz ist dabei die Behandlung mit Mitotane im Sinne einer Monotherapie oder in Kombination mit anderen Chemotherapeutika, wie Cisplatin, Etoposid und Vincristin. Substanzen wie Suramin und Gossipol haben sich klinisch nicht durchgesetzt. Neue therapeutische Ansätze beinhalten die Tumorvakzinierung oder die Applikation antiangiogenetischer Substanzen.

Das Radiopharmakon Metaiodbenzylguanidin (MIBG) oder Kombinationschemotherapien wie z. B. Cyclophosphamid, Vincristin und Dacarbizin werden zur systemischen Therapie des malignen Phäochromozytoms eingesetzt, insbesondere die Wirksamkeit des letzten Ansatzes bedarf aber noch weiterer klinischer Evaluierung.

Abstract

Systemic treatment of advanced-stage adrenal malignancies is most often only palliative. Mitotane alone or in combination with other chemotherapeutic agents such as cisplatin, etoposide, and vincristine are established therapeutic concepts for the treatment of metastatic adrenal cancer. Suramin and gossypol are rarely employed. New therapeutic options are tumor vaccination and treatment with antiangiogenic drugs.

Metaiodobenzylguanidine as a radiotherapeutic drug or chemotherapeutic combination therapies that include cyclophosphamide, vincristine, and dacarbazine are applied for systemic treatment of malignant pheochromocytomas.. However, the clinical efficacy of the latter regimen needs further evaluation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Abraham J, Bakke S, Rutt A et al. (2002) A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94: 2333

    Article  PubMed  Google Scholar 

  2. Arlt W, Reincke M, Siekmann L et al. (1994) Suramin in adrenocortical cancer: limited efficacy and serious toxicity. Clin Endocrinol (Oxf) 41: 299

    Google Scholar 

  3. Averbuch SD, Steakley CS, Young RC et al. (1988) Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109: 267

    PubMed  Google Scholar 

  4. Bellantone R, Ferrante A, Boscherini M et al. (1997) Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery 122: 1212

    Article  PubMed  Google Scholar 

  5. Berruti A, Terzolo M, Paccotti P et al. (1992) Favorable response of metastatic adrenocortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Report of two cases. Tumori 78: 345

    PubMed  Google Scholar 

  6. Berruti A, Terzolo M, Sperone P et al. (2005) Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12: 657

    Article  PubMed  Google Scholar 

  7. Bukowski RM, Wolfe M, Levine HS et al. (1993) Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 11: 161

    PubMed  Google Scholar 

  8. Edstrom Elder E, Hjelm Skog AL, Hoog A et al. (2003) The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol 29: 278

    Article  PubMed  Google Scholar 

  9. Eriksson B, Oberg K, Curstedt T et al. (1987) Treatment of hormone-producing adrenocortical cancer with o,p’DDD and streptozocin. Cancer 59: 1398

    PubMed  Google Scholar 

  10. Flack MR, Pyle RG, Mullen NM et al. (1993) Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metab 76: 1019

    Article  PubMed  Google Scholar 

  11. Hartley A, Spooner D, Brunt AM (2001) Management of malignant phaeochromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands. Clin Oncol (R Coll Radiol) 13: 361

    Google Scholar 

  12. Kasperlik-Zaluska AA, Migdalska B, Makowska A (1994) Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 73: 1533

    Google Scholar 

  13. Keiser HR, Goldstein DS, Wade JL et al. (1985) Treatment of malignant pheochromocytoma with combination chemotherapy. Hypertension 7: 118

    PubMed  Google Scholar 

  14. Khan TS, Imam H, Juhlin C et al. (2000) Streptozocin and o,p’DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 11: 1281

    Article  PubMed  Google Scholar 

  15. La Rocca RV, Stein CA, Danesi R et al. (1990) Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect. J Clin Endocrinol Metab 71(2): 497–504

    PubMed  Google Scholar 

  16. Latronico AC, Chrousos GP (1997) Extensive personal experience: adrenocortical tumors. J Clin Endocrinol Metab 82: 1317

    Article  PubMed  Google Scholar 

  17. Le Blanc M, Russo J, Kudelka AP et al. (2002) An in vitro study of inhibitory activity of gossypol, a cottonseed extract, in human carcinoma cell lines. Pharmacol Res 46: 551

    Article  PubMed  Google Scholar 

  18. Loh KC, Fitzgerald PA, Matthay KK et al. (1997) The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 20: 648

    PubMed  Google Scholar 

  19. Lubitz JA, Freeman L, Okun R (1973) Mitotane use in inoperable adrenal cortical carcinoma. JAMA 223: 1109

    Article  PubMed  Google Scholar 

  20. Luton JP, Cerdas S, Billaud L et al. (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322: 1195

    PubMed  Google Scholar 

  21. Maezawa T, Yonese J, Tsukamoto T et al. (2001) Low dose CVD chemotherapy as a tumor dormancy therapy for extra-adrenal malignant pheochromocytoma: a case report. Nippon Hinyokika Gakkai Zasshi 92: 593

    PubMed  Google Scholar 

  22. Manger WM, Gifford RW Jr, Hoffman BB (1985) Pheochromocytoma: a clinical and experimental overview. Curr Probl Cancer 9: 15

    Google Scholar 

  23. Ng L, Libertino JM (2003) Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 169: 5

    Article  PubMed  Google Scholar 

  24. Schteingart DE, DohertyGM, Gauger PG et al. (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12: 667

    Article  PubMed  Google Scholar 

  25. Shapiro B, Sisson JC, Wieland DM et al. (1991) Radiopharmaceutical therapy of malignant pheochromocytoma with [131 I]metaiodobenzylguanidine: results from ten years of experience. J Nucl Biol Med 35: 269

    PubMed  Google Scholar 

  26. Sisson JC, Shapiro B, Shulkin BL et al. (1999) Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy. Am J Clin Oncol 22: 364

    Article  PubMed  Google Scholar 

  27. Sisson J C (2002) Radiopharmaceutical treatment of pheochromocytomas. Ann N Y Acad Sci 970: 54

    PubMed  Google Scholar 

  28. Stein CA, LaRocca RV, Thomas R et al. (1989) Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 7: 499

    PubMed  Google Scholar 

  29. Turner HE, Harris AL, Melmed S et al. (2003) Angiogenesis in endocrine tumors. Endocr Rev 24: 600

    Article  PubMed  Google Scholar 

  30. Williamson SK, Lew D, Miller GJ et al. (2000) Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 88: 1159

    Article  PubMed  Google Scholar 

  31. Wooten MD, King DK (1993) Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 72: 3145

    PubMed  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Klinik für Urologie, Eberhard-Karls-Universität, Hoppe-Seyler-Straße 3, 72076, Tübingen

    M. Horstmann, A. S. Merseburger, A. Stenzl &  M. Kuczyk

Authors
  1. M. Horstmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. S. Merseburger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Stenzl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Kuczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Kuczyk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Horstmann, M., Merseburger, A.S., Stenzl, A. et al. Systemische Therapie maligner Nebennierentumoren. Urologe 45, 605–608 (2006). https://doi.org/10.1007/s00120-006-1038-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-006-1038-2

Schlüsselwörter

Keywords

Search

Navigation